These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1166 related articles for article (PubMed ID: 32278676)
1. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E; Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676 [TBL] [Abstract][Full Text] [Related]
2. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA; Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889 [TBL] [Abstract][Full Text] [Related]
3. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218 [TBL] [Abstract][Full Text] [Related]
5. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936 [TBL] [Abstract][Full Text] [Related]
6. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Morris V; Overman MJ; Jiang ZQ; Garrett C; Agarwal S; Eng C; Kee B; Fogelman D; Dasari A; Wolff R; Maru D; Kopetz S Clin Colorectal Cancer; 2014 Sep; 13(3):164-71. PubMed ID: 25069797 [TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549 [TBL] [Abstract][Full Text] [Related]
8. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens. Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808 [TBL] [Abstract][Full Text] [Related]
9. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. Sastre J; García-Alfonso P; Viéitez JM; Cano MT; Rivera F; Reina-Zoilo JJ; Salud-Salvia A; Quintero G; Robles-Díaz L; Safont MJ; La Casta A; Gil S; Polo E; Asensio-Martínez E; García-Paredes B; López RL; Guillot M; Valladares-Ayerbes M; Aranda E; Díaz-Rubio E; ESMO Open; 2021 Apr; 6(2):100062. PubMed ID: 33711671 [TBL] [Abstract][Full Text] [Related]
10. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136 [TBL] [Abstract][Full Text] [Related]
12. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. Noepel-Duennebacke S; Arnold D; Hertel J; Tannapfel A; Hinke A; Hegewisch-Becker S; Reinacher-Schick A Clin Colorectal Cancer; 2018 Dec; 17(4):e733-e739. PubMed ID: 30145148 [TBL] [Abstract][Full Text] [Related]
13. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335 [TBL] [Abstract][Full Text] [Related]
14. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E; Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161 [TBL] [Abstract][Full Text] [Related]
15. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295 [TBL] [Abstract][Full Text] [Related]
16. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156 [TBL] [Abstract][Full Text] [Related]
17. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715 [TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C Oncology; 2014; 87(1):7-20. PubMed ID: 24968756 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. Bencsikova B; Bortlicek Z; Halamkova J; Ostrizkova L; Kiss I; Melichar B; Pavlik T; Dusek L; Valik D; Vyzula R; Zdrazilova-Dubska L BMC Gastroenterol; 2015 Mar; 15():37. PubMed ID: 25888291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]